New Avenues for Targeted Therapies and Biomarkers In Anaplastic Large Cell Lymphoma

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

G Egger receives funding from the Austrian Science Foundation (P27616), the Herzfelder’sche Familienstiftung and the Ludwig Boltzmann Gesellschaft. SD Turner receives funding from Bloodwise, Alex Hulme Foundation, Francesca Richardson Fund, Cancer Research UK and Children with Cancer UK. Both SD Turner and G Egger are in receipt of funding from the European Union’s Horizon 2020 Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) under grant agreement no. 675712 (ALKATRAS). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

G Egger receives funding from the Austrian Science Foundation (P27616), the Herzfelder’sche Familienstiftung and the Ludwig Boltzmann Gesellschaft. SD Turner receives funding from Bloodwise, Alex Hulme Foundation, Francesca Richardson Fund, Cancer Research UK and Children with Cancer UK. Both SD Turner and G Egger are in receipt of funding from the European Union’s Horizon 2020 Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) under grant agreement no. 675712 (ALKATRAS). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.